Quick Answer
CG Oncology, Inc. reported Net Income of -$161.00 million for fiscal year 2025.
CG Oncology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$161.00M -82.9% |
-$88.04M -81.1% |
-$48.61M | — |
| Diluted EPS | -$2.08 -47.5% |
-$1.41 +91.0% |
-$15.65 | — |
| Total Assets | $791.59M +4.9% |
$754.80M +278.7% |
$199.30M | — |
| Cash and Equivalents | $32.49M -87.4% |
$257.07M +3009.9% |
$8.27M | — |
| Long-Term Debt | $3.00M | $0.00 | — | — |
| Stockholders Equity | $752.60M +2.6% |
$733.38M +695.8% |
-$123.10M -58.4% |
-$77.69M |
| R&D Expense | $116.64M +42.1% |
$82.10M +79.5% |
$45.75M | — |
| Operating Income | -$190.77M -66.4% |
-$114.67M -106.8% |
-$55.45M | — |
| Shares Outstanding | 80.69M +6.0% |
76.15M +1358.3% |
5.22M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$43.81M | -114.7% | -5.8% |
| Diluted EPS | September 30, 2025 | -$0.57 | -90.0% | -5.6% |
| Total Assets | September 30, 2025 | $729.91M | +32.1% | +4.1% |
| Cash and Equivalents | September 30, 2025 | $45.15M | +4.0% | +208.7% |
| Long-Term Debt | September 30, 2025 | $3.00M | — | — |
| Stockholders Equity | September 30, 2025 | $687.64M | +28.1% | +2.6% |
| R&D Expense | September 30, 2025 | $27.88M | +42.1% | -11.0% |
| Operating Income | September 30, 2025 | -$51.13M | -80.7% | -4.9% |
| Shares Outstanding | September 30, 2025 | 78.28M | +15.9% | +2.7% |
- CG Oncology, Inc. reported Net Income of -$161.00 million for fiscal year 2025.
- CG Oncology, Inc. showed a decrease of -82.9% in Net Income compared to the prior fiscal year.
- CG Oncology, Inc. reported Diluted EPS of $2.08 per share (loss) for fiscal year 2025.
- CG Oncology, Inc. showed a decrease of -47.5% in Diluted EPS compared to the prior fiscal year.
- CG Oncology, Inc. reported Total Assets of $791.59 million for fiscal year 2025.
- CG Oncology, Inc. showed an increase of +4.9% in Total Assets compared to the prior fiscal year.
- CG Oncology, Inc. reported Cash and Equivalents of $32.49 million for fiscal year 2025.
- CG Oncology, Inc. showed a decrease of -87.4% in Cash and Equivalents compared to the prior fiscal year.
- CG Oncology, Inc. reported Long-Term Debt of $3.00 million for fiscal year 2025.
- CG Oncology, Inc. reported Stockholders Equity of $752.60 million for fiscal year 2025.
- CG Oncology, Inc. showed an increase of +2.6% in Stockholders Equity compared to the prior fiscal year.
- CG Oncology, Inc. reported R&D Expense of $116.64 million for fiscal year 2025.
- CG Oncology, Inc. showed an increase of +42.1% in R&D Expense compared to the prior fiscal year.
- CG Oncology, Inc. reported Operating Income of -$190.77 million for fiscal year 2025.
- CG Oncology, Inc. showed a decrease of -66.4% in Operating Income compared to the prior fiscal year.
- CG Oncology, Inc. reported Shares Outstanding of 80.69 million shares for fiscal year 2025.
- CG Oncology, Inc. showed an increase of +6.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: